JPRN-UMIN000009085已完成未知
Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer - Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Continuous administration trial of Phase2 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Biliary Tract Cancer and recurrent Biliary Tract Cancernresectable Advanced and Recurrent Biliary Tract CancerJPRN-UMIN000006436OncoTherapy Science, Inc.7
已完成
2 期
Continuous administration trial of phase II study of BSC-1 in patients with ATAdult T-cell leukemia/lymphomaJPRN-jRCT2080224825Minophagen Pharmaceutical Co., Ltd.10
已完成
2 期
A phase IIb randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients BLING IISevere Sepsis in the Intensive Care patientInfection - Studies of infection and infectious agentsBlood - Other blood disordersACTRN12612000138886HMRC442
进行中（未招募）
1 期
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004537-25-FRCentre Léon Bérard25
进行中（未招募）
不适用
Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours(TET) or Histiocitosi X (LCH) with Imatinib Mesylate. - TETIMAXPatients affected by TET or LCHEUCTR2007-006119-22-ITIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II